OTC Markets OTCQB - Delayed Quote USD

Elite Pharmaceuticals, Inc. (ELTP)

Compare
0.5000
+0.0001
+(0.02%)
At close: January 10 at 3:00:00 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
71,171.2750
56,625.1280
34,155.1140
32,262.1170
25,380.7490
Cost of Revenue
39,339.6000
30,268.0250
17,561.0930
17,466.7630
13,513.6110
Gross Profit
31,831.6750
26,357.1030
16,594.0210
14,795.3540
11,867.1380
Operating Expense
17,221.4360
15,568.3340
12,625.2120
9,724.6440
9,762.6150
Operating Income
14,610.2390
10,788.7690
3,968.8090
5,070.7100
2,104.5230
Net Non Operating Interest Income Expense
-823.3150
-567.7040
-1,105.2540
-191.6900
-259.0840
Other Income Expense
-20,559.0840
-9,757.9730
1,122.3190
1,425.4090
2,299.0750
Pretax Income
-6,772.1600
463.0920
3,985.8740
6,304.4290
4,144.5140
Tax Provision
-383.9250
-19,645.5390
424.0280
-1,736.4370
-943.9070
Earnings from Equity Interest Net of Tax
946.4070
--
--
857.3790
943.9070
Net Income Common Stockholders
-6,388.2350
20,108.6310
3,561.8460
8,898.2450
5,088.4210
Average Dilution Earnings
550.0720
--
--
-1,425.4090
-1,237.1320
Diluted NI Available to Com Stockholders
-6,388.2350
20,108.6310
3,561.8460
8,898.2450
3,851.2890
Basic EPS
-0.01
0.02
0.00
0.01
0.01
Diluted EPS
-0.01
0.02
0.00
0.01
0.00
Basic Average Shares
1,042,622.3760
1,015,443.3630
1,012,911.3460
1,010,607.7130
942,997.8750
Diluted Average Shares
1,048,889.7420
1,023,225.6230
1,012,911.3460
1,010,607.7130
942,997.8750
Total Operating Income as Reported
14,610.2390
10,788.7690
3,676.0020
5,070.7100
2,104.5230
Total Expenses
56,561.0360
45,836.3590
30,186.3050
27,191.4070
23,276.2260
Net Income from Continuing & Discontinued Operation
-6,388.2350
20,108.6310
3,561.8460
8,898.2450
5,088.4210
Normalized Income
9,548.4274
23,280.0899
2,558.9223
7,772.1719
3,410.0963
Interest Income
21.3740
20.9180
7.4530
0.1260
0.5140
Interest Expense
844.6890
588.6220
1,112.7070
191.8160
259.5980
Net Interest Income
-823.3150
-567.7040
-1,105.2540
-191.6900
-259.0840
EBIT
-5,927.4710
1,051.7140
5,098.5810
6,496.2450
4,404.1120
EBITDA
-4,010.3600
2,523.2980
6,443.2640
7,930.9540
5,928.7030
Reconciled Cost of Revenue
38,992.9450
30,176.3890
17,479.8620
17,226.9930
13,302.8670
Reconciled Depreciation
1,917.1110
1,471.5840
1,344.6830
1,434.7090
1,524.5910
Net Income from Continuing Operation Net Minority Interest
-6,388.2350
20,108.6310
3,561.8460
8,898.2450
5,088.4210
Total Unusual Items Excluding Goodwill
-16,894.4360
-4,014.5050
1,122.3190
1,425.4090
2,299.0750
Total Unusual Items
-16,894.4360
-4,014.5050
1,122.3190
1,425.4090
2,299.0750
Normalized EBITDA
12,884.0760
6,537.8030
5,320.9450
6,505.5450
3,629.6280
Tax Rate for Calcs
0.0001
0.0002
0.0001
0.0002
0.0003
Tax Effect of Unusual Items
-957.7736
-843.0461
119.3953
299.3359
620.7503
3/31/2021 - 2/24/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BIOA BioAge Labs, Inc.
4.9400
-2.95%
 
SCYX SCYNEXIS, Inc.
1.2300
0.00%
 
VDRM ViaDerma, Inc.
0.0110
+4.76%
 
SXTC China SXT Pharmaceuticals, Inc.
0.4693
-1.82%
 
BFRI Biofrontera Inc.
1.1200
-5.08%
 
MEDXF Medexus Pharmaceuticals Inc.
2.7430
+0.85%
 
PTPI Petros Pharmaceuticals, Inc.
0.3761
+3.32%
 
SBFM Sunshine Biopharma, Inc.
2.9300
-1.35%
 
TLRY Tilray Brands, Inc.
1.2300
-10.22%
 
BGM BGM Group Ltd.
11.35
-6.28%